{{DISPLAYTITLE:Indium (<sup>111</sup>In) capromab pendetide}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 458271478
| image =  
| drug_name = Indium (<sup>111</sup>In) capromab pendetide
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = o
| target = prostatic carcinoma cells
<!-- Clinical data -->
| tradename = Prostascint
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 151763-64-3
| CAS_supplemental = (capromab)<br />{{CAS|148805-91-8}} (pendetide)
| ATC_prefix = V09
| ATC_suffix = IB04
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201579
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}

'''Indium (<sup>111</sup>In) capromab pendetide''' (trade name '''Prostascint''') is used to image the extent of [[prostate cancer]].<ref name="PMID 18279057">{{Cite journal| first1 = M. J.
| title = Indium-111 capromab pendetide in the management of recurrent prostate cancer
| last1 = Manyak
| journal = Expert Review of Anticancer Therapy
| volume = 8
| issue =   2
| pages = 175â€“81
| year = 2008
| pmid =   18279057 
| doi = 10.1586/14737140.8.2.175
}}</ref> Capromab is a [[mouse]] [[monoclonal antibody]] which recognizes [[prostate specific membrane antigen]] (PSMA) from prostate cancer cells and normal prostate tissue.  It is linked to [[pendetide]], a derivative of [[DTPA]].<ref>[http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list67.pdf WHO Drug Information]</ref> Pendetide acts as a [[chelating agent]] for the [[radionuclide]] [[indium-111]]. Following an intravenous injection of Prostascint, imaging is performed using [[single photon emission computed tomography]] (SPECT).<ref name=" PMID 18279057" />

Early trials with yttrium ([[Yttrium-90|<sup>90</sup>Y]]) capromab pendetide were also conducted.<ref>{{Cite journal
| doi = 10.1089/cbr.1999.14.99
| volume = 14
| issue = 2
| pages = 99
| last = Kahn
| first = Daniel
| author2=J. Christopher Austin |author3=Robert T. Maguire |author4=Sara J. Miller |author5=Jack Gerstbrein |author6=Richard D. Williams
| title = A Phase II Study of [<sup>90</sup>Y] Yttrium-Capromab Pendetide in the Treatment of Men with Prostate Cancer Recurrence Following Radical Prostatectomy
| journal = Cancer Biotherapy & Radiopharmaceuticals
| year = 1999
}}</ref>

== References ==
{{reflist}}

{{Radiopharmaceuticals}}
{{Monoclonals for tumors}}

[[Category:Radiopharmaceuticals]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}